Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1 1

Status

Completed 3

Sponsor Class

NIH 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

CNS 7Lymphoid 5Gynecologic 5Other solid neoplasm 4Head & Neck 4Genitourinary 4Other hematologic neoplasm 3Breast 3Thoracic 2Dermatologic 2Tumor-Agnostic 1Sarcoma 1Plasma cell 1Other neoplasm 1Myeloid 1

Conditions

Breast Neoplasms 3Camurati-Engelmann Syndrome 1

Interventions

Trastuzumab 732Paclitaxel 695Cyclophosphamide 647Docetaxel 560Capecitabine 486Letrozole 437Fulvestrant 400Carboplatin 398Doxorubicin 341Tamoxifen 308Anastrozole 279pembrolizumab 274exemestane 258Epirubicin 251pertuzumab 240Radiotherapy 239palbociclib 224Bevacizumab 222Gemcitabine 215Vinorelbine 197Lapatinib 181130-nm albumin-bound paclitaxel 172Magnetic Resonance Spectroscopy 164Albumin-Bound Paclitaxel 157eribulin 154Surveys and Questionnaires 152Exercise 151Drug Therapy 141Taxes 134Fluorouracil 133

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Fenretinide × Breast × Clear all
NCT00003099 2012-07-30

Chemoprevention Therapy Plus Surgery in Treating Women With Breast Cancer

M.D. Anderson Cancer Center

Phase 2 Completed
52 enrolled
Breast

Breast Neoplasms

NCT00002646 2012-01-05

Hormone Therapy in Treating Postmenopausal Women With Receptor-Positive Breast Cancer

National Cancer Institute (NCI)

Phase 3 Completed
1,500 enrolled
Breast

Breast Neoplasms

NCT00001378 2008-03-04

A Pilot Trial of Tamoxifen and 4-HPR (4-N-Hydroxyphenyl Retinamide) in Persons at High Risk for Developing Breast Cancer

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
75 enrolled
Breast

Breast Neoplasms, Camurati-Engelmann Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡